Health Providers Training Act

House Bill

H.R. 5385

119th Congress

Health Providers Training Act

In Committee

Introduced:Sep 16, 2025

Primary Sponsor

Greg Landsman

Representative

Democratic

OH-1

Cosponsors

1

Quick Stats

Policy Area

Health

Summary

This bill would require pharmacy benefit managers (PBMs) that work with Medicare drug plans to report more detailed information about the costs and prices of prescription drugs. This is intended to make the drug pricing process more transparent and hold PBMs accountable for the prices they negotiate.

Latest Action

Referred to the Subcommittee on Health.

SponsorGreg Landsman (D-OH)

Introduced9/16/2025

StatusReferred to the House Committee on Ways and Means.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Health Providers Training Act

This bill would require pharmacy benefit managers (PBMs) that work with Medicare drug plans to report more detailed information about the costs and prices of prescription drugs. This is intended to make the drug pricing process more transparent and hold PBMs a

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill would require pharmacy benefit managers (PBMs) that work with Medicare drug plans to report more detailed information about the costs and prices of prescription drugs. This is intended to make the drug pricing process more transparent and hold PBMs accountable for the prices they negotiate.

Bill Number: 5385
Sponsor: Greg Landsman (D-OH)
Introduced: 9/16/2025
Status: Referred to the House Committee on Ways and Means.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Health Providers Training Act
Bill Number: 5385
Sponsor: Greg Landsman (D-OH)
Status: Referred to the House Committee on Ways and Means.
Introduced: 9/16/2025
Summary: This bill would require pharmacy benefit managers (PBMs) that work with Medicare drug plans to report more detailed information about the costs and prices of prescription drugs. This is intended to make the drug pricing process more transparent and hold PBMs accountable for the prices they negotiate

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill would require pharmacy benefit managers (PBMs) that work with Medicare drug plans to report more detailed information about the costs and prices of prescription drugs. This is intended to make the drug pricing process more transparent and hold PBMs accountable for the prices they negotiate.

Last updated: 12/29/2025

Official Summary

Congressional Research Service summary

Medicare PBM Accountability ActThis bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

Key Points

Main provisions of the bill

PBMs must disclose information about how they calculate drug costs and performance measures for Medicare drug plans.
PBMs must provide an itemized list of all prescription drugs dispensed, including information about costs, claims, and affiliated pharmacies.
Medicare drug plan sponsors can audit PBMs to ensure they are complying with the new reporting requirements.
The Government Accountability Office must study ways to streamline reporting requirements for health plans and PBMs related to drug price transparency.

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it would primarily impact Medicare beneficiaries and taxpayers by increasing transparency around prescription drug pricing and the role of PBMs in the Medicare drug benefit program. This could lead to lower drug prices and out-of-pocket costs for seniors and people with disabilities enrolled in Medicare.

Policy Areas

Primary Policy Area

Health

Related Subjects

Accounting and auditing

Congressional oversight

Contracts and agency

Drug safety, medical device, and laboratory regulation

Government information and archives

Government studies and investigations

Health care costs and insurance

Prescription drugs

Retail and wholesale trades

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

5385, 119th Congress (2025). "Health Providers Training Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-5385

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.